Treatment of Patients With Solid Tumor Cancers Via Intermediate-Size Patient Population Expanded Access Investigational New Drug (IND)
Latest Information Update: 17 Jun 2025
At a glance
- Drugs MNPR 101 DFO*89Zr (Primary) ; MNPR 101 PCTA 177Lu Monopar Therapeutics (Primary)
- Indications Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Monopar Therapeutics
Most Recent Events
- 11 Jun 2025 According to a Monopar Therapeutics, company announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration (FDA).
- 27 May 2025 New trial record